Free Trial

ESSA Pharma (EPIX) FDA Events

ESSA Pharma logo
$1.72 -0.03 (-1.71%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
FDA Events for ESSA Pharma (EPIX)

This section highlights FDA-related milestones and regulatory updates for drugs developed by ESSA Pharma (EPIX). Over the past two years, ESSA Pharma has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as EPI-7386. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.

EPI-7386 + Enzalutamide - FDA Regulatory Timeline and Events

EPI-7386 + Enzalutamide is a drug developed by ESSA Pharma for the following indication: Metastatic Castration-Resistant Prostate Cancer. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

ESSA Pharma FDA Events - Frequently Asked Questions

As of now, ESSA Pharma (EPIX) has not received any FDA approvals for its therapy in the last two years.

In the past two years, ESSA Pharma (EPIX) has reported FDA regulatory activity for EPI-7386 + Enzalutamide.

The most recent FDA-related event for ESSA Pharma occurred on September 13, 2024, involving EPI-7386 + Enzalutamide. The update was categorized as "Presentation," with the company reporting: "ESSA Pharma Inc announced the presentation of updated dose escalation data from its Phase 1/2 study evaluating masofaniten (formerly EPI-7386) in combination with enzalutamide at the 2024 European Society for Medical Oncology (ESMO) Congress, taking place September 13-17, 2024, in Barcelona, Spain.."

Currently, ESSA Pharma has one therapy (EPI-7386 + Enzalutamide) targeting the following condition: Metastatic Castration-Resistant Prostate Cancer.

More FDA Event Resources from MarketBeat

  • NDA: New Drug Application
  • ANDA: Abbreviated New Drug Application
  • sNDA: Supplemental New Drug Application
  • BLA: Biologics License Application
  • sBLA: Supplemental Biologics License Application
  • FDA Approved: Approved by the FDA
  • EMA: European Medicines Agency
  • CE Mark: European Union Certification
  • NMPA: China National Medical Products Administration
  • MHLW: Japanese Ministry of Health
  • FDA Meeting: Consultation with FDA
  • Pre-IND: Pre-Investigational New Drug Meeting
  • Breakthrough Therapy: Special FDA designation for promising therapies
  • Fast Track: Accelerated FDA approval pathway
  • Orphan Drug: Designation for rare disease treatments
  • RPD: Rare Pediatric Disease Designation
  • RMAT: Regenerative Medicine Advanced Therapy
  • DSMB Review: Data Safety Monitoring Board Review
  • IDMC Review: Independent Data Monitoring Committee
  • MAA: MHRA Marketing Authorization Application
  • RTF: Refusal to File (Rejected Application)
  • 510(k): FDA Clearance for Medical Devices
  • Rolling Submission: Staggered regulatory review process

This page (NASDAQ:EPIX) was last updated on 7/11/2025 by MarketBeat.com Staff
From Our Partners